About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | A Study Of PF-06263507 In Patients With Advanced Solid Tumors

A Study Of PF-06263507 In Patients With Advanced Solid Tumors

NCT01891669·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Pfizer

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available.
Performance Status of 0 or 1.
Adequate bone marrow, kidney, liver, and heart function.

You may not be if

Brain metastases requiring steroids.
Major surgery or anti-cancer therapy within 4 weeks of study treatment start.
Active bacterial, fungal or viral infection.

The record

StatusTerminated

PhasePhase 1

Taking part26

StartedAug 2013

UpdatedJan 9, 2019

Conditions

Neoplasms Carcinoma, Non Small Cell Lung Breast Neoplasms Ovarian Neoplasms

Where4

Brigham and Women's Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States